Is Silo Pharma, Inc. (SILO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 152.5% / 30% | 0.0% / 30% | 462.07% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 152.5% / 33% | 0.0% / 33% | 462.07% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 95.5% / 33% | 0.0% / 33% | 462.07% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 152.5% / 33% | 0.0% / 33% | 462.07% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 95.5% / 33% | 0.0% / 50% | 462.07% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 65.2% | |
| Operating Margin | -6388.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -86.1% | |
| Return on Assets (ROA) | -44.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$4M |
| Free Cash Flow | -$4M |
| Current Ratio | 8.7 |
| Total Assets | $7M |
Price & Trading
| Last Close | $0.38 |
| 50-Day MA | $0.34 |
| 200-Day MA | $0.51 |
| Avg Volume | 986K |
| Beta | 0.6 |
|
52-Week Range
$0.22
| |
About Silo Pharma, Inc. (SILO)
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Silo Pharma, Inc. (SILO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Silo Pharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Silo Pharma, Inc.'s debt ratio?
Silo Pharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Silo Pharma, Inc.'s key financial metrics?
Silo Pharma, Inc. has a market capitalization of $5M, and revenue of $72,102. Return on equity stands at -86.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.